中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
24期
11495-11499
,共5页
祝宝让%杨武威%李静%蔡建明%孙顶%崔建国
祝寶讓%楊武威%李靜%蔡建明%孫頂%崔建國
축보양%양무위%리정%채건명%손정%최건국
寡核苷酸类,反义%STAT3转录因子%腺癌%辐射增敏药
寡覈苷痠類,反義%STAT3轉錄因子%腺癌%輻射增敏藥
과핵감산류,반의%STAT3전록인자%선암%복사증민약
Oligodeoxynucleotides,Antisense%STAT3 transcription factor%Adenocarcinoma%Radiation-sensitizing agents
目的:探讨STAT3反义寡核苷酸(antisense oligodeoxynucleotide,ASODN)对肺腺癌裸鼠移植瘤辐射增敏的影响,为提高恶性肿瘤的辐射敏感性提供新的思路和方法。方法建立裸鼠体内肺腺癌移植瘤动物模型,待瘤体直径>0.5 cm后,瘤内多点注射STAT3 ASODN,给药剂量:15 mg/kg,1次/d,连续2周,给药后2 h联合γ射线局部照射总剂量20 Gy,每次2 Gy,每周5次,连续2周,照射剂量率0.75 Gy/min,定期测量肿瘤体积,绘制肿瘤生长曲线;测量肿瘤质量,计算抑瘤率;记录存活情况,估算生存率,绘制生存曲线,计算总生存期;免疫组化检测肿瘤组织细胞内STAT3蛋白表达变化情况;Western Blot 检测肿瘤组织内 P-STAT3、Bcl-xL、CyclinD1蛋白表达情况。结果反义(antisense,AS)+照射(irradiation,IR)组肿瘤体积治疗第8天开始明显小于其余各组肿瘤体积(P<0.05);AS+IR组的抑瘤率为68.4%,高于IR组与AS组的之和;AS+IR组的平均总生存期为(28.38±0.96)d,明显高于IR组及无义(nonsense,NS)+IR组(P<0.005);STAT3蛋白及其下游Bcl-xL、CyclinD1蛋白表达变化明显下降, STAT3蛋白磷酸化水平也降低。结论 STAT3反义寡核酸能够增强肺腺癌裸鼠移植瘤的辐射敏感性,具有良好的放疗增敏剂临床应用开发前景。
目的:探討STAT3反義寡覈苷痠(antisense oligodeoxynucleotide,ASODN)對肺腺癌裸鼠移植瘤輻射增敏的影響,為提高噁性腫瘤的輻射敏感性提供新的思路和方法。方法建立裸鼠體內肺腺癌移植瘤動物模型,待瘤體直徑>0.5 cm後,瘤內多點註射STAT3 ASODN,給藥劑量:15 mg/kg,1次/d,連續2週,給藥後2 h聯閤γ射線跼部照射總劑量20 Gy,每次2 Gy,每週5次,連續2週,照射劑量率0.75 Gy/min,定期測量腫瘤體積,繪製腫瘤生長麯線;測量腫瘤質量,計算抑瘤率;記錄存活情況,估算生存率,繪製生存麯線,計算總生存期;免疫組化檢測腫瘤組織細胞內STAT3蛋白錶達變化情況;Western Blot 檢測腫瘤組織內 P-STAT3、Bcl-xL、CyclinD1蛋白錶達情況。結果反義(antisense,AS)+照射(irradiation,IR)組腫瘤體積治療第8天開始明顯小于其餘各組腫瘤體積(P<0.05);AS+IR組的抑瘤率為68.4%,高于IR組與AS組的之和;AS+IR組的平均總生存期為(28.38±0.96)d,明顯高于IR組及無義(nonsense,NS)+IR組(P<0.005);STAT3蛋白及其下遊Bcl-xL、CyclinD1蛋白錶達變化明顯下降, STAT3蛋白燐痠化水平也降低。結論 STAT3反義寡覈痠能夠增彊肺腺癌裸鼠移植瘤的輻射敏感性,具有良好的放療增敏劑臨床應用開髮前景。
목적:탐토STAT3반의과핵감산(antisense oligodeoxynucleotide,ASODN)대폐선암라서이식류복사증민적영향,위제고악성종류적복사민감성제공신적사로화방법。방법건립라서체내폐선암이식류동물모형,대류체직경>0.5 cm후,류내다점주사STAT3 ASODN,급약제량:15 mg/kg,1차/d,련속2주,급약후2 h연합γ사선국부조사총제량20 Gy,매차2 Gy,매주5차,련속2주,조사제량솔0.75 Gy/min,정기측량종류체적,회제종류생장곡선;측량종류질량,계산억류솔;기록존활정황,고산생존솔,회제생존곡선,계산총생존기;면역조화검측종류조직세포내STAT3단백표체변화정황;Western Blot 검측종류조직내 P-STAT3、Bcl-xL、CyclinD1단백표체정황。결과반의(antisense,AS)+조사(irradiation,IR)조종류체적치료제8천개시명현소우기여각조종류체적(P<0.05);AS+IR조적억류솔위68.4%,고우IR조여AS조적지화;AS+IR조적평균총생존기위(28.38±0.96)d,명현고우IR조급무의(nonsense,NS)+IR조(P<0.005);STAT3단백급기하유Bcl-xL、CyclinD1단백표체변화명현하강, STAT3단백린산화수평야강저。결론 STAT3반의과핵산능구증강폐선암라서이식류적복사민감성,구유량호적방료증민제림상응용개발전경。
Objective To investigate the STAT3 antisense oligodeoxynucleotides (ASODN) radiosensitization on lung adenocarcinoma in nude mice, to explore new ideas and approaches to increase the radiosensitivity of malignant tumor. Methods Establishment lung adenocarcinoma xenografts in nude mice animal models, the tumor diameter greater than 0.5 cm, were injected STAT3 ASODN intratumoral multi-point, dosage:15 mg/kg, for 2 weeks, after administration of 2H combined with gamma ray local irradiation, irradiation dose of 20 Gy, 2 Gy each time, 5 times a week, for 2 weeks, according to radiation dose rate 0.75 Gy/min, regular measurement of tumor volume, tumor growth curve; measuring tumor weight inhibitory rate was calculated; recording survival, estimating survival, survival curves plotted to calculate overall survival;immunohistochemical detection of tumor cells STAT3 protein expression changes; Western Blot detection of tumor tissue P-STAT3, Bcl-xL, CyclinD1 protein expression. Results AS+irradiation treatment group tumor volume was smaller than the rest groups began eighth days of tumor volume (P<0.05), STAT3 ASODN combined with radiation can significantly delay tumor growth;the tumor inhibition rate of AS+irradiation group reach 68.4%, higher than the the sum of simple irradiation group and simple ASODN administration group; AS+irradiation group, the average overall survival was (28.38±0.96) days, significantly higher than the irradiation group and NS+irradiation group (P<0.005);STAT3 and its downstream protein Bcl-xL, CyclinD1 protein expression was significantly decreased, STAT3 phosphorylation levels were also reduced. Conclusion STAT3 antisense oligonucleotide can enhance the radiosensitivity of lung adenocarcinoma in nude mice, has good radiosensitizer clinical application and development prospects.